About Steven Altschuler
Steve Altschuler is chief executive officer and a director of ai3Bio, a company developing lipid nanoparticle and antibody treatments meant to remove the immune cells that drive autoimmune disease. He is also managing director of Healthcare Ventures at Ziff Capital Partners, an investment firm that funds and helps build biotechnology companies focused on cellular and molecular approaches to disease. He currently serves as board chair of 89Bio, Lexeo Tx, Port Tx and Avista Tx.
He formerly held chief executive positions at Children's Hospital of Philadelphia and the University of Miami Health System. He co-founded Spark Therapeutics and served as its board chair from the company's founding until its acquisition in 2019. He is a board member of WW, ImVaX and Stellular Bio. He is also a trustee of the POLG Foundation and the Institute of Innovative Genomics at the University of California, Berkeley.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Steven Altschuler in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Steven Altschuler works with at each company, as listed on that company's latest Form D.
